Search clinical trials for: Regorafenib (BAY73-4506)

Total 6235 results

Bayer

Completed

Sorafenib Drug Drug Interaction Study in Healthy Male Subjects

Drug Interactions

Germany
Bayer

Completed

Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

Ovarian Neoplasms

Poland, Belgium, Spain, Hong Kong, Korea, Republic of, Canada, Italy, Singapore, Germany, United States, Netherlands, France, Japan, Finland
Bayer

Completed

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (ORACLE)

Chronic Myelogenous Leukemia

United States, France
Bayer

Completed

A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China, Taiwan, Korea, Republic of
Bayer

Completed

Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib (OPTIMIS)

Carcinoma, Hepatocellular

Japan, Turkey, Austria, Czechia, Hungary, Israel, Russian Federation, Slovakia, Switzerland, India, Korea, Republic of, France, Mexico, Indonesia, Singapore, Thailand, Canada, Greece, Netherlands, Spain, Taiwan, Poland, Brazil, China, D... and more
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb; Bayer

Active, not recruiting

A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer

Esophagogastric Cancer | HER2-Negative

United States
Bayer
Amgen

Completed

Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer

Carcinoma, Renal Cell

United States, United Kingdom
Bayer

Completed

Hepatic Impairment Study

Liver Disease

United States
Bayer

Completed

Sorafenib/ Carboplatin/ Paclitaxel in Patients With Solid Tumors

Neoplasms

United States
Bayer

Completed

BAY43-9006 - Phase II in Advanced Breast Cancer

Breast Cancer | Breast Neoplasms

Italy, Germany
Bayer

Completed

Phase I Study of Sorafenib Dosed Continuously With Cyclophosphamide and Doxorubicin

Cancer

Canada
Sarah K. Lynam MD
Bayer

Recruiting

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer

Ovarian Cancer | Serous Ovarian Cancer

United States
Bayer

Terminated

Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy

Carcinoma, Renal Cell
Bayer

Completed

Effect of Riociguat on Bone Metabolism

Pharmacology, Clinical

Germany
China Medical University, China
The People's Hospital of Liaoning Province; The First Affiliated Hospital of... and other collaborators

Not yet recruiting

Regorafenib Plus Raltitrexed as Third-line Treatment in Advanced Colorectal Cancer Patients

Colorectal Neoplasms | Regorafenib | Raltitrexed | Third-line Treatment
Bayer

Completed

Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) (STORM)

Carcinoma, Hepatocellular

Belgium, France, Spain, China, Hong Kong, United States, Canada, Switzerland, Germany, Portugal, Taiwan, Japan, Russian Federation, Singapore, Austria, United Kingdom, Korea, Republic of, Australia, New Zealand, Mexico, Brazil, Italy and more
Bayer

Completed

Pharmacokinetics and Safety of a Single Intravenous Infusion of BAY 79-4980

Hemophilia A

United States
Bayer

Completed

A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma

Carcinoma, Hepatocellular

Belgium, Israel, Italy, France, United States
Bayer

Terminated

Research Study for Patients With Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

United States
Bayer

Completed

A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (SHARP)

Carcinoma, Hepatocellular

Belgium, Italy, Spain, Canada, Switzerland, Germany, Greece, Russian Federation, France, United States, United Kingdom, Chile, New Zealand, Australia, Romania, Bulgaria, Croatia, Israel, Peru, Poland, Mexico, Brazil, Argentina
EpicentRx, Inc.

Completed

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer (ROCKET)

Colorectal Neoplasms

United States
Bayer

Withdrawn

Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer (POWER-NEXT)

Carcinoma, Renal Cell
Bayer

Completed

Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

Carcinoma, Hepatocellular

Korea, Republic of, Japan
Bayer

Withdrawn

Coronary Vasomotor Response After Riociguat Exposure (CORONARIES)

Coronary Artery Disease

United States
Peking Union Medical College Hospital

Unknown

Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer

Advanced Colorectal Carcinoma

China
Bayer
Merck Sharp & Dohme LLC

Terminated

Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients

Cystic Fibrosis

Germany, United States, France, Canada, Belgium, Netherlands, United Kingdom
Bayer

Completed

Post Marketing Surveillance Study on Emselex After Launch in Germany

Overactive Bladder

Germany
Yehua Shen

Not yet recruiting

HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure

HCC - Hepatocellular Carcinoma
Bayer

Terminated

Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity

Multiple Sclerosis | Overactive Detrusor

Germany
M.D. Anderson Cancer Center
Bayer

Withdrawn

Phase II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Glioblastoma | Gliosarcoma
Bayer
Onyx Therapeutics, Inc.

Completed

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Breast Cancer

Spain, Ireland, Japan, Russian Federation, United States, Australia, Austria, Czechia, Belgium, China, Germany, Hungary, Israel, South Africa, United Kingdom, France, Greece, Puerto Rico, Italy, Canada, Poland, Sweden, Argentina
Edgewise Therapeutics, Inc.

Recruiting

A Study of EDG-5506 in Children With Duchenne Muscular Dystrophy (LYNX) (LYNX)

Duchenne Muscular Dystrophy

United States
Bayer

Completed

FREEDOM - First Real-Life Evaluation of Enablex Done in ZA Overactive Bladder Patients During a 3 Months Period (FREEDOM)

Overactive Bladder

South Africa
Ospedale Policlinico San Martino
Bayer; Associazione Italiana per la Ricerca sul Cancro; Gruppo Italiano per lo...

Recruiting

Adjuvant Durvalumab Plus Regorafenib vs Untreated Control in Stage IV Colorectal Cancer Patients With no Evidence of Disease (NED): VIVA Trial (VIVA)

Colorectal Cancer Stage IV | No Evidence of Disease State

Italy
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)

Colorectal Cancer

United States, Australia, Canada, Chile, China, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Malaysia, Norway, Russian Federation, South Africa, Spain, Taiwan, Turkey, Ukraine, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study

Colorectal Cancer

China
BeiGene

Completed

Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC

Hepatocellular Carcinoma (HCC)

China, Italy, United States, Germany, Japan, Taiwan, Czechia, Spain, United Kingdom, France, Poland
Bayer

Completed

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors (RIFTOS MKI)

Thyroid Neoplasms

United States, Japan, Turkey, Russian Federation, India, Germany, France, Mexico, Philippines, Greece, Netherlands, Spain, Taiwan, Brazil, Egypt, Argentina, Algeria, Lebanon, Saudi Arabia
Bayer

Completed

Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma (SEARCH)

Carcinoma, Hepatocellular

Belgium, France, Spain, Hong Kong, United States, Canada, Germany, Greece, New Zealand, Russian Federation, Australia, Taiwan, Austria, United Kingdom, China, Israel, Korea, Republic of, Bulgaria, Brazil, Poland, Italy, Colombia, South... and more
Bayer

Completed

A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma

Melanoma

France, United Kingdom
Edgewise Therapeutics, Inc.

Completed

Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

Nervous System Diseases | Genetic Diseases, Inborn | Musculoskeletal Diseases | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Healthy Volunteer

United States
Centre Leon Berard

Recruiting

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. (MegaMOST)

Malignant Solid Tumor

France
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC... and other conditions

United States
M.D. Anderson Cancer Center
Bayer

Terminated

Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma

Glioblastoma | Gliosarcoma

United States
Bayer
Amgen

Completed

Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma

Melanoma | Cancer

United States
Bayer

Completed

BAY43-9006 (Sorafenib) Versus Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma

Carcinoma, Renal Cell

Russian Federation, France, United States, Germany, Poland, Ukraine, United Kingdom
Erasmus Medical Center

Completed

The Effects of the Proton Pump Inhibitor Esomeprazole on the Bioavailability of Regorafenib (REGORA)

Colorectal Neoplasms | Gastrointestinal Stromal Tumors

Netherlands
Linkoeping University

Completed

Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis

Fatigue | Paresis | Cognitive Dysfunction | Paresthesia | Radicular Pain

Sweden
Abramson Cancer Center at Penn Medicine

Completed

To Determine the Safety of Regorafenib, Hydroxychloroquine, and Entinostat Metastatic Colorectal Cancer

Colorectal Cancer

United States
Jules Bordet Institute

Recruiting

Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer (REGINA)

Rectal Cancer Stage II | Rectal Cancer Stage III

Belgium, France

Search clinical trials for: Regorafenib (BAY73-4506)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tunisia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations